Lycia Therapeutics, Inc. has taken a significant step towards its initial public offering (IPO) by filing an amended registration statement with the Securities and Exchange Commission (SEC). The company plans to offer 14.7 million shares of its common stock, with an expected price range between $16.00 and $18.00 per share. This IPO is crucial for Lycia as it seeks to raise capital to support its growth and development in the biological products sector.
Founded in Delaware and based in South San Francisco, Lycia Therapeutics operates in the biological products industry, specifically focusing on products that do not include diagnostic substances. The company is categorized under the Standard Industrial Classification (SIC) code 2836. As an emerging growth company, Lycia is eligible for reduced reporting requirements, which can facilitate a smoother path to public trading.
The amended registration statement, filed on October 20, 2026, is part of Lycia's ongoing efforts to establish itself in the competitive landscape of biological products. The filing indicates that the company has applied to list its shares on the Nasdaq Global Select Market under the ticker symbol “LYCA.” This move is expected to enhance its visibility and accessibility to investors.
According to the filing, the company is preparing for a public offering that could significantly impact its financial standing and market presence. The statement notes, “We are offering 14,700,000 shares of our common stock. This is our initial public offering, and no public market currently exists for our common stock.” This underscores the importance of the IPO for both the company and potential investors.
The IPO is also a reflection of the broader trends in the biological products industry, which has seen increased investment and interest from the market. Companies like Amgen and Gilead Sciences are among the competitors in this space, highlighting the competitive nature of the market that Lycia is entering.
As part of the IPO process, Lycia has granted underwriters a 30-day option to purchase up to an additional 2.2 million shares, which could further increase the total amount raised from the offering. The company has enlisted several financial institutions as joint book-running managers for the IPO, including Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities.
The filing does not specify the exact date when the shares will be available for public trading, stating that delivery is expected to occur as soon as practicable after the effective date of the registration statement. This means that the timeline for the IPO will depend on the SEC’s review and approval process.
In summary, Lycia Therapeutics is poised to make a significant entry into the public market with its upcoming IPO. The company’s focus on biological products, combined with the growing interest in this sector, positions it well for potential success. Investors will be closely watching the developments as the company prepares for its public debut.